Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

News

Online Training Enhances Quality of Life for Adults With Atopic Dermatitis

Riya Gandhi, MA, Associate Editor

A recent study published in JAMA Dermatology revealed the effectiveness of integrated online mindfulness and self-compassion training in significantly improving the quality of life (QOL) for adults living with atopic dermatitis (AD).

The researchers aimed to assess the effectiveness of mindfulness and self-compassion training for enhancing the QOL in adults with AD in a randomized clinical trial of 2 groups: 1 received 8 weekly group sessions consisting of 90 minutes of online mindfulness and self-compassion training, while the other was placed on a waiting list. Both groups were allowed to receive dermatologic treatment except for the medication dupilumab.

The primary outcome measured was the change in the Dermatology Life Quality Index (DLQI) score from baseline to week 13. The intervention group demonstrated a remarkable improvement in the DLQI score, with a between-group difference estimate of -6.34. The standardized effect size at 13 weeks was found to be -1.06, indicating a substantial improvement in QOL. Additionally, all secondary outcomes, including eczema severity, itch- and scratching-related visual analog scales, self-compassion, mindfulness, and psychological symptoms, displayed greater improvements in the intervention group.

“In this randomized clinical trial of adults with AD, integrated online mindfulness and self-compassion training in addition to usual care resulted in greater improvement in skin disease-specific QOL and other patient-reported outcomes, including eczema severity,” concluded the study authors. “These findings suggest that mindfulness and self-compassion training is an effective treatment option for adults with AD.”

 

Reference
Kishimoto S, Watanabe N, Yamamoto Y, et al. Efficacy of integrated online mindfulness and self-compassion training for adults with atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2023;159(6):628-636. doi:10.1001/jamadermatol.2023.0975

Advertisement

Advertisement

Advertisement